Placebo response in clinical trials of depression and its implications for research on chronic neuropathic pain

Neurology

Volumn 65, Issue 12 SUPPL. 4, 2005, Pages

  Dworkin, Robert H ^a   Katz, Jennifer ^a,b   Gitlin, Michael J ^c  

^a UNIVERSITY OF ROCHESTER SCHOOL OF MEDICINE AND DENTISTRY   (United States)

^b STATE UNIVERSITY OF NEW YORK   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; PLACEBO;

CHRONIC PAIN; CLINICAL TRIAL; DATA ANALYSIS; DATA BASE; DEPRESSION; DISEASE DURATION; DISEASE SEVERITY; DRUG EFFICACY; HUMAN; METHODOLOGY; NEUROPATHIC PAIN; OUTCOME ASSESSMENT; OUTCOMES RESEARCH; PATIENT SELECTION; PRIORITY JOURNAL; PUBLICATION; REGISTRATION; RELIABILITY; RESEARCH SUBJECT; REVIEW; STATISTICAL ANALYSIS; VALIDITY; CHRONIC DISEASE; DRUG EFFECT; INTRACTABLE PAIN; NERVOUS SYSTEM; PATHOPHYSIOLOGY; PERIPHERAL NEUROPATHY; PSYCHOLOGICAL ASPECT; STANDARD;

ANTIDEPRESSIVE AGENTS; CHRONIC DISEASE; CLINICAL TRIALS; DEPRESSION; HUMANS; NERVOUS SYSTEM; PAIN, INTRACTABLE; PERIPHERAL NERVOUS SYSTEM DISEASES; PLACEBO EFFECT; RESEARCH DESIGN;

EID: 33645045913     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/wnl.65.12_suppl_4.s7     Document Type: Review

References (113)

1. Watson CP, Evans RJ, Reed K, Merskey H, Goldsmith L, Warsh J. Amitriptyline versus placebo in postherpetic neuralgia. Neurology 1982;32:671-673.
2. Kvinesdal B, Molin J, Froland A, Gram LF. Imipramine treatment of painful diabetic neuropathy. JAMA 1984;251:1727-1730.
3. Max MB, Culnane M, Schafer SC, et al. Amitriptyline relieves diabetic neuropathy pain in patients with normal or depressed mood. Neurology 1987;37:589-596.
4. Backonja M, Beydoun A, Edwards KR, et al., for the Gabapentin Diabetic Neuropathy Study Group: Gabapentin for the symptomatic treatment of painful neuropathy in patients with diabetes mellitus. JAMA 1998;280:1831-1836.
5. Rowbotham MC, Harden N, Stacey B, Bernstein P, Magnus-Miller L, for the Gabapentin Postherpetic Neuralgia Study Group: Gabapentin for the treatment postherpetic neuralgia: a randomized controlled trial. JAMA 1998;280:1837-1842.
6. Farrar JT, Young JP Jr, LaMoreaux L, Werth JL, Poole RM. Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale. Pain 2001;94:149-158.
7. Woolf CJ, Max MB. Mechanism-based pain diagnosis. Anesthesiology 2001;95:241-249.
8. Woolf CJ. Pain: moving from symptom control toward mechanism-specific pharmacologic management. Ann Intern Med 2004;140:441-451.
9. Safirstein B, Tuchman M, Dogra S, et al. Efficacy of lamotrigine in painful diabetic neuropathy: results from two large double-blind trials. J Pain 2005;6(suppl 3):S34. Abstract.
10. Eisenberg E, Luria Y, Braker C, Daoud D, Ishay A. Lamotrigine reduces painful diabetic neuropathy: a randomized, controlled study. Neurology 2001;57:505-509.
11. Vestergaard K, Andersen G, Gottrup H, Kristensen BT, Jensen TS: Lamotrigine for central poststroke pain: a randomized controlled trial. Neurology 2001;56:184-190.
12. Finnerup NB, Sindrup SH, Bach FW, Johannesen IL, Jensen TS. Lamotrigine in spinal cord injury pain: a randomized controlled trial. Pain 2002;96:375-383.
13. Simpson DM, Olney R, McArthur JC, Khan A, Godbold J, Ebel-Frommer K. A placebo-controlled trial of lamotrigine for painful HIV associated neuropathy. Neurology 2000;54:2115-2119.
14. Simpson DM, McArthur JC, Olney R, et al. Lamotrigine for HIV-associated painful sensory neuropathies: a placebo-controlled trial. Neurology 2003;60:1508-1514.
15. Thienel U, Neto W, Schwabe SK, Vijapurkur U. Topiramate in painful diabetic polyneuropathy: findings from three double-blind placebo-controlled trials. Acta Neurol Scand 2004;110:221-231.
16. Raskin P, Donofrio PD, Rosenthal NR, et al. Topiramate vs placebo in painful diabetic neuropathy: analgesic and metabolic effects. Neurology 2004;63:865-873.
17. Backonja M, Glanzman RL. Gabapentin dosing for neuropathic pain: evidence from randomized, placebo-controlled clinical trials. Clin Ther 2003;25:81-104.
18. Dworkin RH, Backonja M, Rowbotham MC, et al. Advances in neuropathic pain: diagnosis, mechanisms, and treatment recommendations. Arch Neurol 2003;60:1524-1534.
19. Neurobiological technologies. Memantine. www.ntii.com/products/memantine. shtml, accessed June 20, 2005.
20. Pellegino RG, Petit WA, Brazg R, et al. Memantine in the treatment of diabetic peripheral neuropathy: a placebo-controlled phase IIB trial. Neurology 2000;54(Suppl):A82. Abstract.
21. Dogra S, Beydoun S, Mazzola J, Hopwood M, Wan Y. Oxcarbazepine in painful diabetic neuropathy: a randomized, placebo-controlled study. Eur J Pain 2005;9:543-554.
22. Max MB. Thirteen consecutive well-designed randomized trials show that antidepressants reduce pain in diabetic neuropathy and postherpetic neuralgia. Pain Forum 1995;4:248-253.
23. Harati Y, Gooch C, Swenson M, et al. Double-blind randomized trial of tramadol for the treatment of the pain of diabetic neuropathy. Neurology 1998;50:1842-1846.
24. Gimbel JS, Richards P, Portenoy RK. Controlled-release oxycodone for pain in diabetic neuropathy: a randomized controlled trial. Neurology 2003;60:927-934.
25. Watson CPN, Moulin D, Watt-Watson J, Gordon A, Eisenhoffer J. Controlled-release oxycodone relieves neuropathic pain: a randomized controlled trial in painful diabetic neuropathy. Pain 2003;105:71-78.
26. Goldstein DJ, Pritchett YL, Detke MJ, Lee TC, Iyengar S. Duloxetine vs. placebo in patients with painful diabetic neuropathy. Pain 2005;116:109-118.
27. Raskin J, Pritchett YL, Wang F, D'Souza DN, Waninger AL, Wernicke JF. A double-blind, randomized multicenter trial comparing duloxetine with placebo in the management of diabetic peripheral neuropathic pain. Pain Med 2005;6:346-356.
28. Lesser H, Sharma U, LaMoreaux L, Poole RM. Pregabalin relieves symptoms of painful diabetic neuropathy. Neurology 2004;63:2104-2110.
29. Rosenstock J, Tuchman M, LaMoreaux L, Sharma U. Pregabalin for the treatment of painful diabetic peripheral neuropathy: a double-blind, placebo-controlled trial. Pain 2004;110:628-638.
30. Richter RW, Portenoy R, Sharma U, Lamoreaux L, Bockbrader H, Knapp LE. Relief of painful diabetic peripheral neuropathy with pregabalin: a randomized, placebo-controlled trial. J Pain 2005;6:253-260.
31. Klein DF, Thase ME, Endicott J, et al. Improving clinical trials: American Society of Clinical Psychopharmacology recommendations. Arch Gen Psychiatry 2002;59:272-278.
32. Khan A, Detke M, Khan SRF, Mallinckrodt C. Placebo response and antidepressant clinical trial outcome. J Nerv Ment Dis 2003;191:211-218.
33. Montgomery SA. Alternatives to placebo-controlled trials in psychiatry. Eur Neuropsychopharmacology 1999;9:265-269.
34. Charney DS, Nemeroff CB, Lewis L, et al. National Depressive and Manic-Depressive Association consensus statement on the use of placebo in clinical trials of mood disorders. Arch Gen Psychiatry 2002;59:262-270.
35. Ernst E, Resch KL. Concept of true and perceived placebo effects. BMJ 1995;311:551-553.
36. Kienle GS, Kiene H. The powerful placebo effect: fact or fiction? J Clin Epidemiol 1997;50:1311-1318.
37. Vase L, Riley JL III, Price DD. A comparison of placebo effects in clinical analgesic trials versus studies of placebo analgesia. Pain 2002;99:443-452.
38. Kleijnen J, de Craen AJM, van Everdingen J, Krol L. Placebo effect in double-blind clinical trials: a review of interactions with medications. Lancet 1994;344:1347-1349.
39. Quitkin FM. Placebos, drug effects, and study design: a clinician's guide. Am J Psychiatry 1999;156:829-836.
40. Kirsch I. Are drug and placebo effects in depression additive? Biol Psychiatry 2000;47:733-735.
41. Whitney CW, Von Korff M. Regression to the mean in treated versus untreated chronic pain. Pain 1992;50:281-285.
42. Schatzberg AF, Kraemer HC. Use of placebo control groups in evaluating efficacy of treatment of unipolar major depression. Biol Psychiatry 2000;47:736-744.
43. Walsh BT, Seidman SN, Sysko R, Gould M. Placebo response in studies of major depression: variable, substantial, and growing. JAMA 2002;287:1840-1847.
44. Robinson DS, Rickels K. Concerns about clinical drug trials. J Clin Psychopharmacol 2000;20:593-596.
45. Rush AJ. The use of placebos in unipolar major depression: the current status. Biol Psychiatry 2000;47:745-747.
46. Montgomery SA. The failure of placebo-controlled studies. Eur Neuropsychopharmacol 1999;9:271-276.
47. Max MB. Small clinical trials. In: Gallin JI, ed. Principles and practice of clinical research. New York: Academic Press, 2002;207-224.
48. Charney DS. The use of placebos in randomized clinical trials of mood disorders: well-justified, but improvements in design are indicated. Biol Psychiatry 2000;47:687-688.
49. Fava M, Evins AE, Dorer DJ, Schoenfeld DA. The problem of the placebo response in clinical trials for psychiatric disorders: culprits, possible remedies, and a novel study design approach. Psychother Psychosom 2003;72:115-127.
50. Fairchild CJ, Rush AJ, Vasavada N, Giles DE, Khatami M. Which depressions respond to placebo? Psychiatry Res 1986;18:217-226.
51. Rabkin JG, Stewart JW, McGrath PJ, Markowitz JS, Harrison W, Quitkin FM. Baseline characteristics of 10-day placebo washout responders in antidepressant trials. Psychiatry Res 1987;21:9-22.
52. Rapaport MH, Hyman M, Zisook S, et al. A comparison of descriptive variables for clinical patients and symptomatic volunteers with depressive disorders. J Clin Psychopharmacol 1996;16:242-246.
53. Moleman P. Symptomatic volunteers different from patients with depressive disorders? J Clin Psychopharmacol 1997;17:323-324.
54. Landin R, DeBrota DJ, DeVries TA, Potter WZ, Demitrack MA. The impact of restrictive entry criterion during the placebo lead-in period. Biometrics 2000;56:271-278.
55. Niklson IA, Reimitz PE, Sennef C. Factors that influence the outcome of placebo-controlled antidepressant clinical trials. Psychopharmacol Bull 1997;33:41-51.
56. Demitrack MA, Faries D, Herrera JM, DeBrota DJ, Potter WZ. The problem of measurement error in multisite clinical trials. Psychopharmacol Bull 1998;34:19-24.
57. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry 1960;23:56-61.
58. Posternak MA, Zimmerman M, Keitner GI, Miller IW. A reevaluation of the exclusion criteria used in antidepressant efficacy trials. Am J Psychiatry 2002;159:191-200.
59. Zimmerman M, Mattia JI, Posternak MA. Are subjects in pharmacological treatment trials of depression representative of patients in routine clinical practice? Am J Psychiatry 2002;159:469-473.
60. Keitner GI, Posternak MA, Ryan CE. How many subjects with major depressive disorder meet eligibility requirements of an antidepressant efficacy trial? J Clin Psychiatry 2003;64:1091-1093.
61. Posternak MA, Zimmerman M. Is there a delay in the antidepressant effect? A meta-analysis. J Clin Psychiatry 2005;66:148-158.
62. Rochon PA, Binns MA, Litner JA, et al. Are randomized control trial outcomes influenced by the inclusion of a placebo group?: a systematic review of nonsteroidal anti-inflammatory drug trials for arthritis treatment. J Clin Epidemiol 1999;52:113-122.
63. Colloca L, Lopiano L, Lanotte M, Benedetti F. Overt versus covert treatment for pain, anxiety, and Parkinson's disease. Lancet Neurol 2004;3:679-684.
64. Khan A, Khan SR, Walens G, Kolts R, Giller EL. Frequency of positive studies among fixed and flexible dose antidepressant clinical trials: an analysis of the Food and Drug Administration summary basis of approval reports. Neuropsychopharmacology 2003;28:552-557.
65. Pablos-Mendez A, Barr RG, Shea S. Run-in periods in randomized trials: implications for the application of results in clinical practice. JAMA 1998;279:222-225.
66. Lang JM. The use of a run-in to enhance compliance. Stat Med 1990;9:87-95.
67. Lang JM, Buring JE, Rosner B, Cook N, Hennekens CH. Estimating the effect of the run-in on the power of the Physicians' Health Study. Stat Med 1991;10:1585-1593.
68. Schnitzer TJ, Gray WL, Paster Z, Kamin M. Efficacy of tramadol in treatment of chronic low back pain. J Rheumatol 2000;27:772-778.
69. Schnitzer TJ, Kamin M, Olson WH. Tramadol allows reduction of naproxen dose among patients with naproxen-responsive osteoarthritis pain: a randomized, double-blind, placebo-controlled study. Arthritis Rheum 1999;42:1370-1377.
70. Rapaport MH, Judd LL, Schettler PJ, et al. A descriptive analysis of minor depression. Am J Psychiatry 2002;159:637-643.
71. Max MB. Neuropathic pain syndromes. In: Max MB, Portenoy RK, Laska EM, eds. The design of analgesic clinical trials. New York: Raven Press, 1991;193-219.
72. Kramer M. Placebo run-in for antidepressant trials. Neuropsychopharmacology 1996;15:105. Letter.
73. Lader M, Scotto JC. A multicentre double-blind comparison of hydroxyzine, buspirone and placebo in patients with generalized anxiety disorder. Psychopharmacology 1998;139:402-406.
74. Greenhill LL, Findling RL, Swanson JM. A double-blind, placebo-controlled study of modified-release methylphenidate in children with attention-deficit/ hyperactivity disorder. Pediatrics 2002;109:e39. Abstract.
75. Liebowitz MR, Stein MB, Tancer M, Carpenter D, Oakes R, Pitts CD. A randomized, double-blind, fixed-dose comparison of paroxetine and placebo in the treatment of generalized social anxiety disorder. J Clin Psychiatry 2002;63:66-74.
76. Adhoute G, Andreassian B, Boccalon H, et al. Treatment of Stage II chronic arterial disease of the lower limbs with the serotonergic antagonist naftidrofuryl: results after 6 months of a controlled, multicenter study. J Cardiovasc Pharmacol 1990;16(suppl 3):S75-80.
77. Varia I, Logue E, O'Connor C, et al. Randomized trial of sertraline in patients with unexplained chest pain of noncardiac origin. Am Heart J 2000;140:367-372.
78. Krogh K, Jensen MB, Gandrup P, et al. Efficacy and tolerability of prucalopride in patients with constipation due to spinal cord injury. Scand J Gastroenterol 2002;37:431-436.
79. Trivedi MH, Rush J. Does a placebo run-in or a placebo treatment cell affect the efficacy of antidepressant medications? Neuropsychopharmacology 1994;11:33-43.
80. Greenberg RP, Fisher S, Riter JA. Placebo washout is not a meaningful part of antidepressant drug trials. Percept Mot Skills 1995;98:688-690.
81. Lee S, Walker JR, Jakul L, Sexton K. Does elimination of placebo responders in a placebo run-in increase the treatment effect in randomized clinical trials? A meta-analytic evaluation. Depress Anxiety 2004;19:10-19.
82. Reimherr FW, Ward MR, Byerly WF. The introductory placebo washout: a retrospective evaluation. Psychiatry Res 1989;30:191-199.
83. Rabkin JG, McGrath P, Stewart JW, Harrison W, Markowitz JS, Quitkin F. Follow-up of patients who improved during placebo. J Clin Psychopharmacol 1986;6:274-278.
84. Quitkin FM, Stewart JW, McGrath PJ, et al. Further evidence that a placebo response to antidepressants can be identified. Am J Psychiatry 1993;150:566-570.
85. Trivedi MH, Baker SM. Clinical significance of monitoring early symptom change to predict outcome. J Clin Psychiatry 2001;62(suppl 4):27-33.
86. Quitkin FM, McGrath PJ, Stewart JW, et al. Placebo run-in period in studies of depressive disorders: clinical, heuristic and research implications. Br J Psychiatry 1998;173:242-248.
87. Ramsay LE. Commentary: placebo run-ins have some value. BMJ 1997;314:7088.
88. Senn S. A personal view of some controversies in allocating treatment to patients in clinical trials. Stat Med 1995;14:2661-2674.
89. Senn S. Are placebo run-ins justified? BMJ 1997; 314: 1191-1193.
90. Skovlund E. Should the single-blind placebo responder exclusion phase be omitted from clinical trials? Nord J Psychiatry 1994;48:159-165.
91. Glynn RJ, Buring JE, Hennekens CH. Concerns about run-in periods in randomized trials. JAMA 1998;279:1526-1527.
92. Evans KR, Sills T, Wunderlich GR, McDonald HP. Worsening of depressive symptoms prior to randomization in clinical trials: a possible screen for placebo responders? J Psychiatr Res 2004;38:437-444.
93. Faries DE, Heiligenstein JH, Tollefson GD, Potter WZ. The double-blind variable placebo lead-in period: results from two antidepressant clinical trials. J Clin Psychopharmacol 2001;21:561-568.
94. Detke MJ, Lu Y, Goldstein DJ, Hayes JR, Demitrack MA. Duloxetine, 60 mg once daily, for major depressive disorder: a randomized double-blind placebo-controlled trial. J Clin Psychiatry 2002;63:308-315.
95. Goldstein DJ, Lu Y, Detke MJ, Wiltse C, Mallinckrodt C, Demitrack MA. Duloxetine in the treatment of depression: a double-blind placebo-controlled comparison with paroxetine. J Clin Psychopharmacol 2004;24:389-399.
96. Loebel AD, Hyde TS, Dunner DL. Early placebo response in anxious and depressed patients. J Clin Psychiatry 1986;47:230-233.
97. Katz N. Methodological issues in clinical trials of opioids for chronic pain. Neurology 2005;65(Suppl 4):S32-S49.
98. Turner JA, Deyo RA, Loeser JD, Von Korff M, Fordyce WE. The importance of placebo effects in pain treatment and research. JAMA 1994;271:1609-1614.
99. Hrobjartsson A, Gotzsche PC. Is the placebo powerless? An analysis of clinical trials comparing placebo with no treatment. N Engl J Med 2001;344:1594-1602.
100. Khan A, Warner HA, Brown WA. Symptom reduction and suicide risk in patients treated with placebo in antidepressant clinical trials: an analysis of the Food and Drug Administration database. Arch Gen Psychiatry 2000;57:311-317.
101. Bjune K, Stubhaug A, Dodgson MS, Breivik H. Additive analgesic effect of codeine and paracetamol can be detected in strong, but not moderate, pain after Caesarean section: baseline pain-intensity is a determinant of assay-sensitivity in a postoperative analgesic trial. Acta Anaesthesiol Scand 1996;40:399-407.
102. Averbuch M, Katzper M. Baseline pain and response to analgesic medications in the postsurgery dental pain model. J Clin Pharmacol 2000;40:133-137.
103. Perkins DO, Wyatt RJ, Bartko JJ. Penny-wise and pound-foolish: the impact of measurement error on sample size requirements in clinical trials. Biol Psychiatry 2000;47:762-766.
104. Dworkin RH, Turk DC, Farrar JT, et al. Core outcome measures for chronic pain clinical trials: IMMPACT recommendations. Pain 2005;113:9-19.
105. Jensen MP, Karoly P. Self-report scales and procedures for assessing pain in adults. In: Turk DC, Melzack R, eds. Handbook of pain assessment. 2nd ed. New York: Guilford Press, 2001;15-34.
106. Kane RL, Bershadsky B, Lin WC, Rockwood T, Wood K. Efforts to standardize the reporting of pain. J Clin Epidemiol 2002;55:105-110.
107. Arnold LM, Lu Y, Crofford LJ, et al. A double-blind, multicenter trial comparing duloxetine with placebo in the treatment of fibromyalgia patients with or without major depressive disorder. Arthritis Rheum 2004;50:2974-2984.
108. De Angelis CD, Drazen JM, Frizelle FA, et al. Is this clinical trial fully registered? - A statement from the International Committee of Medical Journal Editors. N Engl J Med 2005;352:2436-2438.
109. Krishnan KR. Efficient trial designs to reduce placebo requirements. Biol Psychiatry 2000;47:724-726.
110. Mattocks KM, Horwitz RI. Placebos, active control groups, and the unpredictability paradox. Biol Psychiatry 2000;47:693-698.
111. Leber P. Not in our methods, but in our ignorance. Arch Gen Psychiatry. 2002;59:279-280.
112. Jensen TS, Baron R. Translation of symptoms and signs into mechanisms in neuropathic pain. Pain 2003;102:1-8.
113. Rowbotham MC. Mechanisms of neuropathic pain and their implications for the design of clinical trials. Neurology 2005;65(Suppl 4):S66-S73.